| value |
{"case_id":"case_4c5a7dc411c219d5" {"case_id":"case_4c5a7dc411c219d5","confidence":0.3,"corroboration":{"agreement":{"count_score":0.5,"down_count":0,"magnitude_weighted_score":0.5,"majority_direction":"neutral","neutral_count":2,"score":0.5,"up_count":0},"base_score":0.5657,"claim_graph":{"case_signal_families":["market","filing"],"case_source_domains":["fool.com","sec.gov"],"claims":[{"agreement_score":0.6,"claim_id":"claim_8f89b1d3fea293fd","conflict":false,"direction":"neutral","evidence_count":1,"family_coverage":1,"quality_score":0.4353,"source_coverage":1,"source_trust":0.97,"statement":"Soleno Therapeutics entered into a merger agreement with Neurocrine Biosciences to commence a cash tender offer for its shares.","strength":0.635},{"agreement_score":0.6,"claim_id":"claim_68818e217deffd57","conflict":false,"direction":"neutral","evidence_count":1,"family_coverage":1,"quality_score":0.3963,"source_coverage":1,"source_trust":0.58,"statement":"Soleno Therapeutics stock rose 32% following the announcement of its acquisition by Neurocrine Biosciences.","strength":0.635}],"coverage":{"claim_count":2,"conflicting_claims":0,"dominant_claim_id":"claim_8f89b1d3fea293fd","multi_family_claims":0,"multi_source_claims":0},"score":0.3263},"contradiction":{"flags":[],"has_unresolved_conflict":false,"resolved_claims":[],"resolved_count":0,"score":0.0,"unresolved_claims":[],"unresolved_count":0},"contradiction_flags":[],"evidence_event_count":2,"high_precision_pass":false,"high_trust_source_coverage":1,"independent_source_coverage":2,"low_trust_source_coverage":0,"score":0.5447,"signal_family_coverage":2,"source_trust":{"avg_score":0.775,"domains":[{"count":1,"domain":"sec.gov","score":0.97,"source":"sec_edgar"},{"count":1,"domain":"fool.com","score":0.58,"source":"Nasdaq Markets"}],"high_trust_domains":["sec.gov"],"independent_high_trust_sources":2,"low_trust_domains":[]},"source_trust_score":0.6787},"decision":"monitor","entity_key":"equity:SLNO","evidence_event_count":2,"headline":"Soleno Therapeutics stock rose 32% following the announcement of its acquisition by Neurocrine Biosciences.","personal_relevance_score":0.1,"theme_key":"entity_development","why_now":"Signal convergence: Soleno Therapeutics stock rose 32% following the announcement of its acquisition by Neurocrine Biosciences. [neutral]; Soleno Therapeutics entered into a merger agreement with Neurocrine Bioscience..."}... |